Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deramiocel - Capricor Therapeutics

Next Previous
X
Search
Drug Profile

Deramiocel - Capricor Therapeutics

Alternative Names: Allogeneic adult stem cell therapy for myocardial infarction - Capricor; Allogeneic cardiosphere-derived cells - Capricor; Allogeneic CDCs - Capricor; Allogenic derived cells - Capricor; CAP-1002

Latest Information Update: 16 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Capricor
  • Developer Capricor; Capricor Therapeutics; Medical University of South Carolina
  • Class Exosome therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Duchenne muscular dystrophy
  • Phase II COVID 2019 infections
  • Phase I/II Cardiomyopathies
  • Discontinued Heart failure; Myocardial infarction

Most Recent Events

  • 02 Jan 2025 Capricor Therapeutics completes submission of Biologics License Application to the US FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
  • 02 Jan 2025 Preregistration for Duchenne muscular dystrophy (In adults, In the elderly, In adolescents, In children) in USA (IV)
  • 20 Nov 2024 Deramiocel - Capricor Therapeutics receives Advanced Therapy Medicinal Product (ATMP) designations for Duchenne muscular dystrophy in European Union

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top